Case Comprehensive Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Case Comprehensive Cancer Center sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).
Case Comprehensive Cancer Center: 407 sponsored US clinical trials, 55 recruiting.
Case Comprehensive Cancer Center sponsors 407 registered US clinical trials on ClinicalTrials.gov, 55 of them currently recruiting, and 257 completed. 13 of these trials are in Phase 3-4 (later-stage) and 203 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
Case Comprehensive Cancer Center ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
257 of 325 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (79.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
407 total, page 5 of 9
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
NCT02129582
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
NCT02070458
MRI Before Biopsy in Diagnosing Patients With Prostate Cancer
NCT02131207
Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors
NCT02135562
Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention
NCT01951885
NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer
NCT02103634
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
NCT01959477
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma
NCT01973062
Tailoring Patient Education to Perceived Risk for Falls in Hospitalized Oncology Patients
NCT02081794
Assessment of Novel MRI Quantification Free Breathing Technique in Evaluation of Liver Lesions
NCT02095678
Enzalutamide in Patients With High-risk Prostate Cancer
NCT01927627
Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers
NCT02129569
FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents
NCT02055586
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
NCT01954784
Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer
NCT01959490
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
NCT01894061
Intensive Education in Increasing Understanding of Lymphedema in Patients With Breast Cancer Undergoing Surgery
NCT02073045
Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial
NCT02024685
Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery
NCT01939028
Improving Erectile Function and Quality of Life After Prostate Cancer Treatment
NCT01996852
Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer
NCT01876238
PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer
NCT01892540
PET-MRI in Diagnosing Patients With Colon or Rectal Cancer
NCT01807117
PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer
NCT02287636
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
NCT02084147
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
NCT01666730
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
NCT01730157
Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study
NCT01685346
Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer
NCT01740154
The Effects of Perioperative Music Therapy on Women Undergoing Breast Biopsy Surgery
NCT01669733
High-Dose Stereotactic Radiation for Prostate Cancer
NCT01664130
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
NCT01652794
Screening and Risk Factors of Colon Neoplasia
NCT01647776
Positron Emission Tomography/Magnetic Resonance Imaging in Patients
NCT01557881
PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors
NCT01652768
Music Therapy on Nausea and Pain for Autologous Stem Cell
NCT01487031
A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer
NCT02128373
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
NCT01408043
Assisted Exercise in Obese Endometrial Cancer Patients
NCT01870947
A Cognitive- Behavioral Play Intervention for Siblings of Children Diagnosed With Cancer
NCT01704885
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
NCT01395537
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
NCT01301963
Exercising Our ABC's (African- American Breast Cancer Survivors)
NCT01684579
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
NCT01658319
Assessment of Candidate Protein Expression in Breast Cancer Specimens
NCT00918892
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
NCT01192815
Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT)
NCT01337492
Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer
NCT01158222
Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
NCT01127009
Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome
NCT01165996
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 87 |
| Phase 2 | 116 |
| Phase 3 | 12 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Case Comprehensive Cancer Center pipeline
55 recruiting of 407 indexed (14% open); 257 completed (63%).
Phase mix: 13 late (III/IV) vs 203 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Case Comprehensive Cancer Center: open-pipeline peers nationwide
Peers matched on 407 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Case Comprehensive Cancer Center sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 407 trials (± recruiting share)
- University of Nebraska · 407 trials · 13% recruiting
- Takeda · 408 trials · 12% recruiting
- University of Kansas Medical Center · 408 trials · 23% recruiting
- St. Jude Children's Research Hospital · 410 trials · 22% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Beth Israel Deaconess Medical Center · 14% recruiting · 488 trials
- Wayne State University · 13% recruiting · 163 trials
- University of Michigan · 13% recruiting · 1,327 trials
- Albany Medical College · 13% recruiting · 52 trials
Related
What to do with this Case Comprehensive Cancer Center page
407 registered trials is a research-attention snapshot, not an endorsement of Case Comprehensive Cancer Center or any single study.
- 55 of Case Comprehensive Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Case Comprehensive Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Case Comprehensive Cancer Center pipeline card: 407 registered trials from official public datasets.Report a data error.